Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes (DF-IL2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01353833
First received: May 12, 2011
Last updated: April 20, 2012
Last verified: May 2011

May 12, 2011
April 20, 2012
May 2011
October 2011   (final data collection date for primary outcome measure)
Kinetic parameters of Treg proportions variation within CD4+ T cells in peripheral blood [ Time Frame: from Day+0 to Day+60 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01353833 on ClinicalTrials.gov Archive Site
Improvement of residual secretion of insulin assessed by the AUC of peptide C during a standardized test meal in IL-2 vs placebo treated patients [ Time Frame: at Day+0 and Day+60 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes
Dose-effect Relationship of Repeated Administration of Low-dose IL-2 Versus Placebo on the Kinetic of Regulatory T Cells in Patients With Type 1 Diabetes

IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to control the autoimmune destruction of beta-cells in patients with Type 1 Diabetes (T1D). The investigators recently showed that low dose IL-2 is well tolerated in patients with an autoimmune disease. The investigators aim to use IL-2 to induce/stimulate Treg in T1D patients. This study will investigate the dose effect relationship of low dose IL-2 for Treg induction such as to optimize the risk benefit ratio for this treatment in T1D. By Treg induction, the investigators aim to protect the remaining/regenerating β-cells from autoimmune destruction, thus improving or even curing T1D.

Rationale:

Type 1 diabetes (T1D) results from an autoimmune destruction of beta-pancreatic cells that regulatory T cells (Treg) fail to control. This is in part due to a deficit in production of, or response to, interleukin 2 (IL-2). This cytokine is essential to Treg development, survival and function. Importantly, while IL-2 also contributes to the activation of effector T cells (Teff), IL-2/IL-2 receptor signal transduction threshold is much lower for Treg than Teff. Thus low-dose IL-2 could be a specific Treg inducer/stimulator.

The investigators then recently showed that low-dose IL-2 could cure recent onset diabetes in NOD mice that develop spontaneous diabetes considered as the best model of human T1D. A 5-day treatment with IL-2 could cure over 30% of the mice versus 0% for controls.

With these premises, the investigators propose to explore if Treg induction could be obtained in patients who may have a deficit in production of, or response to, IL-2. Defining the dose effect relationship of low dose IL-2 for Treg induction will optimize the risk benefit ratio for IL-2 in T1D.

Principal objective:

To define the dose-effect relationship of low dose IL-2 for Treg induction in patient with recent onset diabetes

Evaluation Criteria:

  • Efficacy Kinetic variation of Treg proportions within CD4+ T cells in peripheral blood from Day+0 to Day+60.
  • Tolerance Evaluation by clinical exams, laboratory tests and monitoring of side effects. The criterion for terminating the study will be the occurrence of one serious unexpected side effect in the month following IL-2 first administration in at least 2 patients.

Study plan:

After inclusion (Day0), the patient receives a 5-day course of IL-2 or placebo. Patients are randomized in 4 arms receiving either a placebo, or IL-2 doses of 0,33 - 1 or 3 millions UI/day. Laboratory follow-up of peripheral blood T cell subsets will be performed at D0 to D6 (daily), D15, D22 and D60 by immunophenotyping and transcriptomics.

Tolerance will be evaluated at D0-6, D15, D22 and D60.

Methodology:

Double blind placebo controlled randomized study, with 4 parallel groups. Patients will have T1D of autoimmune origin attested by the presence of auto-antibodies (at least one of: anti-islet, anti-GAD, anti-IA2 or anti-ZnT8), with a diagnostic inferior or equal to 24 months.

Study length:

Study length = 9 months Patient participation = 2 months Inclusion period = 6 months

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Type 1 Diabetes
Drug: Aldesleukin
0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
Other Name: IL2
  • Placebo Comparator: IL2-4
    Intervention: Drug: Aldesleukin
  • Experimental: IL2-2
    1 millions IU of IL-2 per day
    Intervention: Drug: Aldesleukin
  • Experimental: IL2-3
    3 millions IU of IL-2 per day
    Intervention: Drug: Aldesleukin
  • Experimental: IL2-1
    0.33 millions IU of IL-2 per day
    Intervention: Drug: Aldesleukin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
April 2012
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age [18-50] years;
  • With a T1D:
  • Treated with insulin for ≤ 2 years,
  • With at least one auto-antibody among: anti-islet, anti-GAD, anti-IA2, anti-ZnT8 ;
  • No clinically relevant abnormal value for hematology, biochemistry, liver and kidney function
  • Lymphocyte [1000-4000]/ mm3
  • Informed consent signed by the patient and the investigator before any intervention necessary for the trial.

Exclusion Criteria:

  • Contra-indications to IL2 :
  • Hypersensibility to IL-2 or its excipients,
  • Severe cardiopathy
  • Ongoing infection requiring antibiotherapy,
  • O2 Saturation ≤ 90 %
  • Severe impairment of a vital organ
  • Previous organ allograft
  • Non authorized concomitant treatment : i.e. immuno-modulators, cytotoxic, drug modifying glycemia
  • Cancer progressing or cured for less than 5 years except for primary basal cell carcinoma or carcinoma in situ of the uterine cervix.
  • Participation to another clinical investigation in < 3 months
  • Pregnant or lactating women
  • Male or female in age of procreation without efficient contraception during the study
  • No affiliation to National Health Insurance
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01353833
P101101, 2010-024499-24
Yes
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Davis Klatzmann, MD, PhD Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP